NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
ZME Science on MSN
New Injectable Therapy Helped Paralyzed Mice Walk and It Just Passed a Major Test on Human Cells
In a petri dish at Northwestern University, researchers grow organoids modeled on the human spinal cord: simplified, lab-made ...
Morning Overview on MSN
New nasal vaccine shields lungs for months from viruses, bacteria, and allergens
Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...
An “immune system reset” eliminated autoimmune, or Type 1, diabetes in mice in a study conducted at. Researchers say the strategy could also have potential for treating other autoimmune diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results